TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either Dato-DXd (6.0 mg/kg intravenously every 3 weeks) or docetaxel (75 mg/m² ...
Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally ...
Explore the potential of polysaccharide microneedles in cancer immunotherapy for effective drug delivery and immune ...
Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
AZoLifeSciences on MSN
Microneedle patches may unlock safer, localized cancer immunotherapy
This review highlights the potential of natural polysaccharide microneedles in cancer immunotherapy, focusing on localized ...
17d
UP: BHU researchers develop first molecular classification of oral cancer to guide precision therapy
VARANASI: A landmark Indian study, \"Unveiling Oral Cancer’s Molecular Blueprint: A Novel Classification to Guide Precision Therapy,\" published in the .
Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic ...
Common diabetes drugs may do more than regulate blood sugar—they could also influence how cancers grow, spread, or slow down.
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine ...
NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 —— ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback